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Abstract 
n-3 Polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), have protective effects against the pancreatic β-cell 
dysfunction through several mechanisms. Thiazolidines are insulin sensitizers and are 
used in treating patients with type 2 diabetes. Our previous study demonstrated that a 
combination of fish oil, which is rich with EPA and DHA, and pioglitazone exerts 
beneficial effects on obesity and diabetes through their actions on the liver and adipose 
tissue. However, it remains largely unknown whether such combination therapy affects 
the pancreas. To answer this question, KK mice, which serve as a model for obesity and 
type 2 diabetes, were treated for 8 weeks with fish oil and pioglitazone. The combined 
regimen suppressed pancreatic islet hypertrophy (mean islet area decreased by an 
average of 49% vs. control) compared with mice treated with fish oil or pioglitazone 
alone (decreased by an average of 21% and 32% vs. control, respectively). Compared 
with the controls, individual or combined treatment significantly increased the 
percentage of β-cell area in the pancreatic islets, significantly decreased endoplasmic 
reticulum stress, and reduced the percentage of apoptotic cell death in the pancreatic 
islets. These findings suggest that fish oil and/or pioglitazone prevents β-cell 
dysfunction by improving the insulin resistance and decreasing the ER stress. 
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1. Introduction 
Chronic hyperglycemia causes overproduction of reactive oxygen species (ROS) by 
the mitochondria of pancreatic cells and gradually causes deterioration of β-cell 
functions such as insulin production and secretion [1, 2]. Hyperinsulinemia that is 
attributed to insulin resistance (IR) triggers β-cell dysfunction through enhanced 
endoplasmic reticulum (ER) stress that is induced by accumulation of unfolded proteins 
in response to intense insulin biosynthesis [3]. These factors ultimately result in β-cell 
damage and apoptosis, which are referred to as glucotoxicity, that contribute to further 
deteriorate type 2 diabetes [1, 4]. Pancreatic inflammation and infiltration of 
macrophages of the pancreatic islets are also closely related to β-cell dysfunction 
through obesity-related IR [3, 5]. These observations suggest that protection against 
functional deterioration of pancreatic β-cells is a beneficial and desirable clinical 
treatment for patients with type 2 diabetes that leads to the prevention of diabetic 
complications. 
Thiazolidines (TZDs) are selective agonists of peroxisome proliferator-activated 
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receptor-γ that are insulin sensitizers and are used to treat patients with type 2 diabetes. 
Evidence indicates that TZDs protect against pancreatic β-cell dysfunction. By 
improving IR with TZDs treatment, high insulin production is reduced and over 
production of ROS and ER stress levels are prevented [6-9]. However, with improving 
abnormal lipid metabolism (lipotoxicity) by TZDs treatment, visceral and ectopic fat in 
insulin-sensitive non-adipose tissues, including the liver, skeletal muscle, and pancreas, 
are redistributed in subcutaneous fat [6, 10, 11]. Animal and clinical studies have 
demonstrated that despite these protective effects of TZDs on β-cells, TZDs increase 
body weight via the accumulation of subcutaneous fat [12, 13]. 
In our previous study, fish oil, which contains n-3 polyunsaturated fatty acids 
(PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
suppressed the increase in body weight that was associated with subcutaneous fat 
accumulation because of TZD treatment, which is considered to occur through the effect 
of n-3 PUFA on hepatic endogenous lipogenesis [14]. n-3 PUFAs protect against β-cell 
dysfunction by ameliorating the lipotoxicity in non-adipose tissues, excess insulin 
secretion, and cytokine-induced inflammation [15, 16]. Kato et al. reported that EPA 
recovered insulin secretion defects on the pancreatic islets in diabetic model mice [17]. 
Moreover, combined treatment with TZDs and n-3 PUFAs exerts beneficial effects for 
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obesity and diabetes through their effects on the liver and skeletal muscle [18-20]. 
We hypothesized that the treatment with fish oil and pioglitazone contributes to 
maintaining islet function and mitigates IR in patients with type 2 diabetes. To address 
this question, we conducted immunohistochemical and morphometrical analyses and 
quantified gene expression in the pancreas of obese KK mice that serve as an animal 
model of patients with mild diabetes. 
 
2. Materials and Methods 
2.1. Animals 
   The animal study was performed in accordance with the “Fundamental Guidelines 
for Proper Conduct of Animal Experiment and Related Activities in Academic Research 
Institutions” (Ministry of Education, Culture, Sports, Science and Technology, Japan, 
Notice No. 71, dated June 1, 2006) and was approved by the Institutional Animal Care 
and Use Committee of the Josai University. KK/Ta mice (males, 6-week-old) were 
obtained from the Tokyo Laboratory Animals Science Co. (Tokyo, Japan) and were fed 
a commercial standard diet (MF, Oriental Yeast Co., Tokyo, Japan) for 1 week to 
stabilize their metabolism. The mice were divided into four weight-matched groups (n = 
5 per group) and were individually housed and fed the experimental diets for 8 weeks at 
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the Josai University Life Science Center. Mice were maintained at 22°C ± 2°C 
temperature and 55% ± 10% humidity with a 12-h light–dark cycle (7:00 AM–7:00 PM). 
The mice were allowed free access to water and food. Mice were fasted for 12 h before 
collecting blood samples and performing computed tomography (CT). 
 
2.2. Diets 
All diets comprised 60 energy% (en%) carbohydrates, 20 en% fats, and 20 en% 
protein (Supplementary Table 1). The safflower oil diet included 20 en% safflower oil 
(Benibana Foods Co., Ltd., Tokyo, Japan) as a lipid source, and the fish oil diet was 
prepared with 10 en% safflower oil and 10 en% fish oil (NOF Co., Tokyo, Japan). These 
diets were designated the SO and FO diets, respectively. The SO and FO diets were 
each supplemented with 0.012 weight% pioglitazone hydrochloride (Wako Pure 
Chemical Industries, Ltd., Osaka, Japan) and were designated the SP and FP diets, 
respectively. These experimental diets, which were supplemented with t-butyl 
hydroquinone (Wako Pure Chemical Industries) to prevent fatty acid oxidation, were 
stored at −30°C. 
 
2.3. Computed tomography 
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At the end of the experiment, mice were fasted for 12 h and anesthetized using 
intraperitoneal injections of pentobarbital sodium (Kyoritsuseiyaku Co., Tokyo, Japan). 
The mouse mode was used for CT scanning (La Theta LCT100, Hitachi Aloka Medical, 
Ltd., Tokyo, Japan). Abdominal compositions were estimated from images of fat slices 
that were acquired at 2-mm intervals between the second and fourth lumbar vertebrae 
using the La Theta software (version 2.10). 
 
2.4. Sample collection 
After CT, we obtained blood samples from the tail vein and measured glucose levels 
using a blood glucose monitoring system (One Touch Ultra, Johnson & Johnson, New 
Brunswick, NJ). The mice were immediately weighed and sacrificed. Blood samples 
were subsequently collected from the inferior vena cava into a tube containing heparin 
(Mochida Pharmaceutical Co., Ltd., Tokyo, Japan) to prevent coagulation, and the tubes 
were centrifuged at 900 × g for 10 min to separate plasma, which was stored at −80°C 
until further analysis. White adipose tissue (WAT) around the epididymis was removed 
and weighed. The pancreas was collected and divided into two sections. The first 
section was fixed with 10% neutral-buffered formalin (Wako Pure Chemical Industries) 
for histology. The second section was immersed in an RNA stabilization reagent for 
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RNA isolation and was stored at −80°C until further use. 
 
2.5. Oxidative stress and evaluation of antioxidative potential 
The diacron of reactive oxygen metabolites (d-ROMs) test and the measurement of 
biological antioxidative potential (BAP) test were performed to evaluate oxidative stress 
and antioxidative potential using the Free Radical Analytical System (Diacron, Grosseto, 
Italy). The d-ROMs data were expressed in conventional units (Carratelli Units, 
U.CARR), and 1 U.CARR corresponds to 0.8 mg/L H2O2. At 0 and 7 weeks after 
initiating experimental diet, blood samples from the tail veins of fasted mice were 
collected into a tube containing heparin and centrifuged at 900 × g for 10 min. All tests 
were conducted following the manufacturer’s instructions. 
 
2.6. Biochemical analyses of plasma 
Plasma insulin and adiponectin concentrations were determined using 
enzyme-linked immunosorbent assay (ELISA) kits (Insulin ELISA kit, Morinaga 
Institute of Biological Science, Tokyo, Japan; Mouse/rat adiponectin ELISA kit, Otsuka 
Pharmaceutical Co., Ltd., Tokyo, Japan). The homeostasis model assessment of insulin 
resistance (HOMA-IR) index was calculated as follows: fasting blood glucose (mg/dL) 
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× fasting plasma insulin (μU/mL)/405. 
 
2.7. Immunohistochemical and morphological analyses 
After fixation, pancreas samples were embedded in paraffin and were stained with 
hematoxylin and eosin (H&E). Immunohistochemical staining of α-cells, β-cells, and 
CCAAT/enhancer-binding protein homologous protein (CHOP) were performed in the 
Kotobiken Medical Laboratories, Inc. (Tokyo, Japan) using anti-glucagon antibody 
(Takara Bio Inc., Shiga, Japan), anti-insulin antibody (Takara Bio Inc.), and anti-CHOP 
antibody (Proteintech Group Inc., Chicago, IL). Specimens were examined using a 
microscope (200× magnification). Images were captured using an Olympus DP21 
camera system (Olympus, Tokyo, Japan), and immunoreactivities were quantified using 
image analysis software (Image J, United States National Institutes of Health). The 
mean area (µm
2
) of the pancreatic islets and their distribution were determined in all 
H&E-stained sections. The percentages of α- and β-cell areas were calculated as 
follows: {glucagon- or insulin-positive area (µm2)/islet area (µm2)} × 100. The 
glucagon- and insulin-positive areas were quantitated using an appropriate threshold 
after altering and adjusting color images to gray scale. 
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2.8. Apoptosis assay 
TdT-mediated dUTP nick-end labeling (TUNEL) assays were performed in 
Kotobiken Medical Laboratories, Inc.. TUNEL-positive nuclei and the total number of 
nuclei in the pancreatic islets were counted using the Image J software. The proportion 
of apoptotic cells to total islet cells was calculated as follows: {number of 
TUNEL-positive nuclei/total number of nuclei} × 100. Cells with undetectable TUNEL 
labeling were designated not detected. 
 
2.9. RNA isolation and quantitative real-time PCR 
TRIzol reagent and a PureLink RNA Mini Kit (Thermo Fisher Scientific Inc., 
Carlsbad, CA) were used according to the manufacturer’s instructions to extract total 
RNA from pancreatic samples immersed in an RNA stabilization reagent. Quantitative 
real-time polymerase chain reactions were performed using total RNA, gene-specific 
primers, QuantiTect SYBR Green RT-PCR kits (QIAGEN N. V. Inc., Hilden, Germany), 
and an ABI Prism 7500 Sequence Detection System (Applied Biosystems, Carlsbad, 
CA). The sense and antisense sequences of primers are shown in Supplementary Table 2. 
Reaction conditions were previously described [14]. The mRNA levels are represented 
as the ratios of each group to those of the SO group. 
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2.10. Statistical methods 
Data are represented as the mean ± standard error of the mean. A significant 
difference (P < 0.05) between groups was identified using one-way ANOVA, followed 
by the Tukey–Kramer test. Values or groups sharing different letters are significantly 
different. All statistical analyses were performed using the Ekuseru-Toukei 2015 (Social 
Survey Research Information Co., Ltd., Tokyo, Japan). 
 
3. Results 
3.1. Total food intake, body weight gain, WAT weight, and abdominal fat mass 
The data for total food intake, body weight gain, epididymal WAT weight, and 
visceral and subcutaneous fat mass (Supplementary Table 3) were similar to those of a 
previous study [14]. 
 
3.2. Evaluation of IR 
The blood glucose level was significantly higher in the SP group than in other 
groups. In contrast, the plasma insulin levels of the SP and FP groups were 82% (P < 
0.05) and 66% (P = 0.0565) lower, respectively, than those of the SO group (Table 1). 
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Similarly, the HOMA-IR indices of the SP and FP groups decreased by 74% (P < 0.05) 
and 68% (P = 0.0569), respectively, than the index of the SO group, indicating that IR 
was reduced by pioglitazone treatment (Table 1). The plasma adiponectin levels 
significantly increased in the pioglitazone-treated groups compared with the untreated 
groups, and the plasma adiponectin level in the FP group was 183% greater than that in 
SP group (Table 1). 
 
3.3. Plasma oxidative stress and anti-oxidative potential markers 
   At 0 and 7 weeks after initiating experimental periods, d-ROMs and BAP levels did 
not significantly differ among all groups (Fig. 1A and 1B). However, after 7 weeks, 
there was a 118% (P = 0.0536) increase than the d-ROMs value of the SO group at 0 
week and a 24% – 43% (FO, P < 0.05; FP, P < 0.05) increase in that of the other groups 
compared with those at 0 week (Fig. 1A). With respect to time, no significant change 
was found in BAP levels with or without fish oil feeding and pioglitazone treatment 
(Fig. 1B). 
 
3.4. Pancreatic islet morphology 
Pancreatic sections that were stained with H&E are shown in Fig. 2A. Numerous 
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hypertrophic pancreatic islets were observed in the SO group. Consistent with plasma 
insulin levels, the islet areas decreased by 32%, 21%, and 49% (P = 0.0948) in the SP, 
FO, and FP groups, respectively, compared with that of the SO group (Fig. 2D). The SO 
group had the lowest percentage of small pancreatic islets (<9999 µm
2
) and the highest 
percentage of large pancreatic islets (>50000 µm
2
). The proportions of small pancreatic 
islets were higher in the FO and FP groups, and the proportions of large pancreatic islets 
were lower in the pioglitazone-treated SP and FP groups than in the SO group. In 
particular, the FP group data were the opposite of the SO group. Moreover, the 
proportion of large pancreatic islets was lower in the FP group than in the SP group (Fig. 
2E). 
The results of the immunohistochemical analyses of glucagon and insulin 
expression in the pancreatic islets are shown in Fig. 2B and 2C, and the percentages of 
areas of α- and β-cells in the pancreatic islets are shown in Fig. 2F and 2G. The 
percentages of the α-cell areas in the pancreatic islets were significantly higher in the SP 
and FO groups, and including tendency (P = 0.0824) in the FP group than in the SO 
group (Fig. 2F). The percentages of β-cell areas in the pancreatic islets were 
significantly increased in the SP, FO, and FP groups compared with the SO group, 
whereas no change was observed among these three groups (Fig. 2G). 
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3.5. Morphometric analysis of pancreatic islet cells 
Immunohistochemical analysis of the expression of CHOP, a marker of ER stress, in 
the pancreatic islets is shown in Fig. 3A. CHOP-positive nuclei were frequently 
observed in sections of the SO group. The percentages of CHOP-positive cells were 
significantly lower in the SP, FO, and FP groups than in the SO group and were <0.1% 
in the FP group (Fig. 3C). TUNEL-positive nuclei were detected in sections of the SO 
and SP groups but not in those of the FO and FP groups (Fig. 3B). There was a decrease 
in the percentage of apoptotic cells in the pancreatic islets of the SP group compared 
with that of the SO group (Fig. 3D). 
 
3.6. Analysis of gene expression in pancreatic tissue 
Among proinflammatory cytokines, the mean levels of mRNA encoding tumor 
necrosis factor-α (TNFα) were higher in the SP group than in the SO group, but no 
significant difference was observed among all groups (Table 2). Furthermore, the levels 
of the mRNAs encoding interleukin-1β (IL1β), monocyte chemoattractant protein-1 
(MCP1), and toll-like receptor 4 (TLR4) were not affected by the fish oil or 
pioglitazone treatment diet. The levels of the mRNA encoding insulin (INS) were 43% 
  
15 
 
and 75% (P = 0.0849) lower in the SP and FP groups, respectively, but were 70% higher 
in the FO group compared with the SO group, even these differences were not 
significant (Table 2). The levels of the mRNA encoding pancreatic and duodenal 
homeobox 1 (PDX1), which regulate the transcription of INS, were lower in the SP 
group (P = 0.0792) and significantly lower in the FP group compared with the SO group 
(Table 2). The levels of the mRNA encoding aquaglyceroporin 7 (AQP7), a glycerol 
channel that regulates insulin production and secretion, were significantly at least 
three-times higher in the pioglitazone-treated groups than in the untreated groups (Table 
2). The levels of the mRNA encoding CHOP were 37% and 38% lower in the SP and FP 
groups, respectively, than in the SO group (Table 2). 
 
4. Discussion and Conclusions 
The structural and functional features of the pancreatic islets change to adapt to 
pathological conditions and to the severity of IR in patients with type 2 diabetes, which 
consider to hypothetical phases of deterioration. In the early stage of IR, expansion of 
pancreatic β-cell mass and increased insulin secretion are induced to produce higher 
insulin levels, which are required to maintain normal blood glucose levels, leading to 
hypertrophy of the pancreatic islets [21]. The overproduction of insulin under conditions 
  
16 
 
of IR causes ER stress through increased the concentration of misfolded proteins in 
response to the high demand for insulin synthesis and excess ER folding capacity [22]. 
Under prolonged intense ER stress in pancreatic β-cells, an apoptotic pathway is 
activated, resulting in β-cell dysfunction that is attributed to a decrease in the β-cell 
mass [23]. 
Here we demonstrated that after the combination treatment of fish oil and 
pioglitazone in KK mice, the mean islet area was lower compared with treatment of fish 
oil or pioglitazone alone. Moreover, fish oil, pioglitazone, or both prevented a reduction 
in the number of insulin-positive β-cells and an enhancement of ER stress in pancreatic 
islets. Furthermore, no apoptotic cells were detected in the islet of the groups that were 
fed fish oil. These results suggest that the combination of fish oil and pioglitazone may 
inhibit β-cell dysfunction and decrease IR thorough different pathways that are specific 
for each treatment without a pioglitazone-induced accumulation of subcutaneous fat and 
increase in body weight. 
Consistent with the results of our previous study [14], the combination of fish oil and 
pioglitazone significantly increased the plasma adiponectin level compared with 
pioglitazone alone. Adiponectin, which is an adipocytokine that is mainly secreted by 
small adipocytes, acts as an insulin-sensitizing hormone to increase insulin secretion, 
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stimulate insulin signaling, and decrease ER stress [24]. TZDs induce the differentiation 
of pre-adipocytes to mature adipocytes in subcutaneous fat, which contribute to the 
redistribution of accumulated fat in non-adipose tissue or that of visceral fat into 
subcutaneous fat [25, 26]. In addition, TZDs are associated with decreasing IR and 
upregulating adiponectin expressions in WAT and increasing plasma adiponectin levels 
[27]. Other studies demonstrated that TZDs decrease ER stress and preserve pancreatic 
morphology and function via several mechanisms, such as the inhibition of β-cell 
overwork by decreasing IR, reducing lipotoxicity, directly upregulating PDX1 
expression, and inhibiting islet cell apoptosis [6, 24, 28]. 
Our results demonstrated that pioglitazone decreased the insulin level, improving 
the IR and increasing the plasma adiponectin level, all of which prevented β-cell 
dysfunction that was induced by ER stress. Moreover, the pioglitazone-treated SP and 
FP groups expressed low PDX1 and INS mRNA levels compared with untreated groups. 
On the other hand, fish oil feeding reduced plasma insulin and lowered the HOMA-IR 
index that was associated with the decreased visceral fat mass, and the reduced mean 
islet area. But, there was no detectable increase in plasma adiponectin levels that were 
detected in the SP group that was administered a single pioglitazone treatment. 
Nascimento et al. found that a diet including fish oil prevents hypertrophy of the 
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pancreatic islets because of reduced fat pad adiposity and body mass in mice that were 
fed a high-fat and -sucrose diet [29]. Altogether, these and the present findings indicate 
that the improvement of islet hypertrophy and β-cell dysfunction by the combination of 
fish oil and pioglitazone are mainly associated with the amelioration of IR through 
increasing the blood adiponectin level by pioglitazone treatment and inhibiting the 
pancreatic β-cell apoptosis by fish oil. 
We were interested to determine that the plasma adiponectin level corresponded 
with the AQP7 mRNA level, which was 1.62-fold higher in the FP group than in the SP 
group, suggesting an inverse association between these parameters and mean islet area. 
Other studies revealed that adiponectin protected against pancreatic β-cell failure by 
increasing the regeneration of β-cells, which is mediated by improved lipid metabolism 
[30]. Moreover, adiponectin counteracted β-cell lipotoxicity that was induced by 
inflammatory cytokines or fatty acids [31]. AQP7 is a channel-forming membrane 
protein that is expressed in the pancreas of mice and rats. AQP7-mediated transport of 
water and glycerol through the membrane contributes to insulin production and 
secretion [32]. Notably, Matsumura et al. found that insulin secretion is impaired in 
Aqp7
−/−
 mice and is associated with the accumulation of triacylglycerol and elevated 
INS mRNA levels in the pancreatic islets and blood insulin levels [33]. We suggest that 
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the combination of fish oil and pioglitazone may contribute an antihypertrophic effect 
on the pancreatic islets, in part, through an adiponectin- and AQP7-mediated 
mechanism of β-cell lipotoxicity and insulin secretion. 
Inflammation and oxidative stress imposed on the pancreas or pancreatic islets are 
critical factors that contribute to β-cell dysfunction [3, 34]. Although n-3 PUFAs and 
TZDs reduce the proinflammatory process [35, 36], we did not observe significant 
differences in the expression of pancreatic genes related to inflammation, such as TNFα, 
IL1β, MCP1, and TLR4. These findings suggested that the improvement of β-cell 
functions by fish oil and pioglitazone treatment of obese KK mice may not be relevant 
to pancreatic inflammation. In contrast, the d-ROMs test, a systemic evaluation of 
oxidative stress, demonstrated that fish oil and pioglitazone treatment suppressed the 
adverse effects of oxidative stress, which were consistent with decreased epididymal 
WAT weight, visceral fat mass, CHOP expression, and TUNEL activity in the pancreatic 
islets. Visceral fat accumulation is strongly associated with increased oxidative stress, 
which causes systemic oxidative stress disorder [37, 38]. The reduction of β-cell 
dysfunction by fish oil and pioglitazone may be leaded to the suppression of systemic 
oxidative stress because of decreased visceral fat levels.  
In conclusion, this study demonstrated that the combination of fish oil and 
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pioglitazone effectively prevented hypertrophy of the pancreatic islets and 
apoptosis-induced cell death through increased insulin sensitivity and decreased ER 
stress, which contributed to the maintenance of pancreatic β-cell functions. 
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Legends for figures 
Figure 1 Plasma diacron of reactive oxygen metabolites (d-ROMs) level (A) and 
biological anti-oxidative potentials (BAP) level (B) at 0 and 7 weeks after the beginning 
of experimental period in KK mice fed SO, SP, FO and FP. Data are represented as 
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mean ± SEM, n = 4 or 5. *: P < 0.05, FO group in comparison with 0 week; **: P < 
0.05, FP group in comparison with 0 week by Tukey–Kramer test. 
 
Figure 2 Islet images of H&E staining (A), glucagon immunostaining (B), insulin 
immunostaining (C), mean islet area (D), islet area proportion (E), percentage of α-cell 
area (F) and percentage of β-cell area (G) in KK mice fed SO, SP, FO and FP for 8 
weeks. Magnification, ×200. Scale bar, 100µm. Data except for (E) are represented as 
mean ± SEM, n = 4 or 5. Groups sharing different letters are significantly different: P < 
0.05 by Tukey–Kramer test.  
 
Figure 3 Islet images of CHOP immunostaining (A), TUNEL staining (B), mean CHOP 
positive ratio (C) and mean TUNEL positive ratio (D) in KK mice fed SO, SP, FO and 
FP for 8 weeks. Arrows indicate positive nuclei with CHOP or TUNEL staining. 
Magnification, ×200. Scale bar, 100µm. Data are represented as mean ± SEM, n =4 or 5. 
Group undetected apoptotic cell in all islet are expressed as not-detected (N.D.). Groups 
sharing different letters are significantly different: P < 0.05 by Tukey–Kramer test.  
 
 
d
-R
O
M
s 
le
v
el
 (
U
.C
A
R
R
)
0
100
200
300
400
0 week 7 weeks
A
**
*
B
0
1000
2000
3000
B
A
P
 l
ev
el
 (
µ
m
o
l/
L
)
SO
SP
FO
FP
0 week 7 weeks
Figure 1 
FOSPSO FP
A
B
C
Figure 2A-2C 
02
4
6
8 a
b
a
ab
SO SP FO FP
P
er
ce
n
ta
g
e 
o
f 
α
-c
el
l 
a
re
a
 
(%
)
0
20
40
60
80
100
a
b
a
a
SO SP FO FP
P
er
ce
n
ta
g
e 
o
f 
β
-c
el
l 
a
re
a
 
(%
)
> 50000 µm2
40000-49999 µm2
30000-39999 µm2
20000-29999 µm2
10000-19999 µm2
< 9999 µm2
0
5
10
15
20
25
30
35
SO SP FO FP
M
ea
n
 i
sl
et
 a
re
a
 
(×
1
0
3
µ
m
2
)
0
20
40
60
80
100
SO SP FO FP
Is
le
t 
a
re
a
 p
ro
p
o
rt
io
n
(%
)
D E
F G
Figure 2D-2G 
B0
0.4
0.8
1.2
1.6
2.0
SO SP FO FP
b
b
b
a
C
H
O
P
 p
o
si
ti
v
e 
ce
ll
s
(%
)
C
A
FOSPSO FP
0
0.02
0.04
0.06
0.08
SO SP FO FP
T
U
N
E
L
 p
o
si
ti
v
e 
ce
ll
s 
(%
)
N.D. N.D.
D
Figure 3
Table 1 Blood glucose, plasma parameters and HOMA-IR index in KK mice fed SO, SP, FO and FP  
for 8 weeks1
Group SO SP FO FP
Blood glucose (mg/dL) 161±20b 243±32a 144±3b 144±5b
Plasma insulin (ng/mL) 15.0±4.4a 2.7±0.8b 9.0±1.8ab 5.1±0.6ab
HOMA-IR index2 147±44a 38±13b 83±16ab 47±6ab
Plasma adiponectin (μg/mL) 9.1±1.3c 37.2±4.1b 11.9±0.7c 68.0±8.5a
1 Data are represented as mean ± SEM, n = 4 or 5. Values sharing different superscript letters in a row are significantly 
different: P < 0.05 by Tukey–Kramer test. 
2 HOMA-IR index was calculated as follows: fasting blood glucose (mg/dL) × fasting plasma insulin (μU/mL)/405.
Group SO SP FO FP
Inflamation
TNFα 1.00±0.19 1.63±0.32 1.44±0.20 1.28±0.13
IL1β 1.00±0.03 1.07±0.03 1.11±0.02 1.08±0.05
MCP1 1.00±0.37 0.79±0.17 0.76±0.24 0.82±0.11
TLR4 1.00±0.22 1.25±0.13 1.14±0.15 1.26±0.15
Insulin synthesis and secretion
INS 1.00±0.22ab 0.57±0.14b 1.70±0.31a 0.25±0.02b
PDX1 1.00±0.08ab 0.74±0.04bc 1.08±0.09a 0.66±0.02c
AQP7 1.00±0.19c 3.11±0.36b 0.93±0.13c 5.07±0.48a
Endoplasmic reticulum stress
CHOP 1.00±0.24 0.63±0.07 0.95±0.12 0.62±0.10
Table 2 Pancreatic gene expression in KK mice fed SO, SP, FO and FP for 8 weeks1, 2
1 Data are represented as mean ± SEM, n = 4 or 5. Values sharing different superscript letters in a row are significantly 
different: P < 0.05 by Tukey–Kramer test.
2 The relative mRNA levels are represented as ratios to SO group.
Ingredients SO SP FO FP
g/kg
Safflower oil 80 80 40 40
Fish oil － － 40 40
Casein 200 200 200 200
Sucrose 104 104 104 104
β-starch 518 518 518 518
Vitamin mix1, 2 10 10 10 10
Mineral mix2 35 35 35 35
Cellulose powder 50 50 50 50
L-cystin 3 3 3 3
t-Butylhydroquinone 0.016 0.016 0.016 0.016
Pioglitazone － 0.12 － 0.12
Supplementary Table 1 Composition of experimental diets 
1 Vitamin and mineral mix were based on the AIN-93G formation. 2 Vitamin mix 
substituted 0.25% sucrose for choline bitartrate. 
Supplementary Table 2 Primers used for real time PCR
Genes Sense (5'→3') Antisense (3' →5')
TNFα TCTCATCAGTTCTATGGCCC GGGAGTAGACAAGGTACAAC
IL1β CTCGGCCAAGACAGGTCGCTC CCCCCACACGTTGACAGCTAGG
MCP1 GGCTCAGCCAGATGCAGT GAGCTTGGTGACAAAAACTACAG
TLR4 CTTCATTCAAGACCAAGCCTTTC AACCGATGGACGTGTAAACCAG
INS AGCAGGAAGGTTATTGTTTC ACATGGGTGTGTAGAAGAAG
PDX1 GATGAAATCCACCAAAGCTC TAAGAATTCCTTCTCCAGCTC
AQP7 TGGGTTTTGGATTCGGAGT TGTTCTTCTTGTCGGTGATGG
CHOP AGTCCCTGCCTTTCACCTT GCTTTGGGATGTGCGTGTG
GAPDH1 TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGAT
1 GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Supplementary Table 3   Total food intake, body weight, epididymal WAT weight and abdominal fat 
masses in KK mice fed SO, SP, FO and FP for 8 weeks1
Group SO SP FO FP
Total food intake (g/mouse) 281±10ab 290±7ab 299±10a 266±5b
Initial body weight (g) 26.1±0.7 26.1±0.6 26.1±0.6 26.1±0.6
Final body weight (g) 38.0±0.4b 42.2±1.4a 36.6±0.7b 38.8±1.0ab
Body weight gain (g) +11.9±0.6b +16.1±0.8a +10.5±0.8b +12.7±0.5b
Epididymal WAT weight (g) 1.34±0.04a 0.97±0.05b 0.91±0.04b 0.83±0.05b
Visceral fat mass (cm3) 1.59±0.13a 1.17±0.13ab 1.07±0.07b 1.04±0.07b
Subcutaneous fat mass (cm3) 0.44±0.02c 0.82±0.04a 0.40±0.03c 0.57±0.03b
1 Data are represented as mean ± SEM, n = 4 or 5. Values sharing different superscript letters in a row are significantly 
different: P < 0.05 by Tukey–Kramer test. 
